EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Visual morbidity in macroprolactinoma: A retrospective cohort study

Yaron Rudman, Hadar Duskin-Bitan, Hiba Masri-Iraqi, Amit Akirov, Ilan Shimon

Clinical Endocrinology · 2024

DOI: 10.1111/cen.15120 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Yaron Rudman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The management of visual field damage in patients with macroprolactinomas is a major therapeutic challenge. We aimed to study the visual morbidity associated with macroprolactinoma and its outcomes following medical and surgical treatment. We aimed to identify predictors of visual recovery.

Methods

We retrospectively reviewed patient's data including clinical presentation, serial pituitary magnetic resonance imaging, laboratory tests, visual symptoms and neuro‐ophthalmologic examination, visual field tests and optical coherence tomography tests. The main outcome was complete visual field recovery. Descriptive analyses were conducted. Predictors of visual recovery were investigated. Patients The study cohort included 150 patients with macroprolactinoma [median follow‐up, 6.0 years (interquartile range (IQR) 2.9–10.6)].

Results

At diagnosis, visual field defects were evident in 40 patients (26.7%). At the end of follow‐up, 24 out of 39 available visual field tests (61.5%) exhibited complete recovery. Patients that achieved complete visual recovery had smaller macroadenomas at diagnosis [30.5 mm (15.0–80.0) vs. 42.0 mm (30.0–85.0), p < .01], lower baseline serum prolactin levels [1414 mcg/L (489–3586) vs. 4119 mcg/L (2715–6315), p < .01], lower rates of central hypogonadism (78.3% vs. 93.3%, p = .05) and central hypothyroidism (20.8% vs. 53.3%, p = .04), lower rates of compressive optic neuropathy (35.3% vs. 87.5%, p = .02) and a better visual acuity (better than 6/8 in both eyes, 93.7% vs. 28.6%, p < .01).

Conclusions

In our cohort of 150 patients with macroprolactinoma, 40 patients (26.7%) presented with visual field defects, of which 61.5% achieved complete visual recovery with treatment. Patients that achieved complete visual recovery presented with smaller macroadenomas, lower serum prolactin levels, lower rates of central hypogonadism and central hypothyroidism, lower rates of compressive optic neuropathy and better visual acuity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsHumansRetrospective StudiesAdultFemaleMaleMiddle AgedVisual FieldsVision DisordersProlactinMagnetic Resonance Imaging

Stichwörter der Autor:innen

cabergolinepituitary macroadenomaprolactinomasurgeryvisual morbidity

Substanzen

Prolactin

Autor:innen und Institutionen

  • Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Rudman, Y., Duskin-Bitan, H., Masri-Iraqi, H., Akirov, A., & Shimon, I. (2024). Visual morbidity in macroprolactinoma: A retrospective cohort study. Clinical Endocrinology. https://doi.org/10.1111/cen.15120

Vancouver

Rudman Y, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I. Visual morbidity in macroprolactinoma: A retrospective cohort study. Clinical Endocrinology. 2024. doi:10.1111/cen.15120

BibTeX
@article{Rudman2024,
  author = {Rudman, Yaron and Duskin-Bitan, Hadar and Masri-Iraqi, Hiba and Akirov, Amit and Shimon, Ilan},
  title = {Visual morbidity in macroprolactinoma: A retrospective cohort study},
  journal = {Clinical Endocrinology},
  year = {2024},
  doi = {10.1111/cen.15120}
}
Kostenlos starten →